NEW YORK, NY – Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company’s strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death. This is in addition to the Company’s combatting traumatic brain injuries and other neuronal diseases. [Read more…]
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
TAMPA, FL – EV Biologics Corp, OTC PINK:YECO, announced that it has completed production of a next-generation, “Gen-2”, MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none. [Read more…]
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]
StemCyte to Supply Raw Materials for Immune Cell Therapies Derived from Umbilical Cord Blood
BALDWIN PARK, Calif., — As international demand for starting substances for use in cell therapy emerges, California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide. [Read more…]
Axol Bioscience and StrataStem to Deliver iPSC-Derived ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.
CAMBRIDGE, England & EDINBURGH, Scotland — Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide range of brain cells, including neurons and neuroinflammatory cells. Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. [Read more…]
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 117
- Next Page »